AZD7687 Multiple Ascending Dose Study

Study identifier:D2710C00002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:2010-019112-21

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1, Single Centre, Single-Blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD7687 after Administration of Multiple Ascending doses in Overweight to Obese but otherwise Healthy Male Subjects

Medical condition

overweight

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD7687, Placebo

Sex

All

Actual Enrollment

Study type

Interventional

Age

20 Years - 45 Years

Date

Study Start Date: 01 Apr 2010

Primary Completion Date: 01 Mar 2011

Study Completion Date: 01 Mar 2011

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

London, United Kingdom

Arms	Assigned Interventions
Experimental: 1	Drug: AZD7687 Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.
Placebo Comparator: 2	Drug: Placebo Oral suspension, once daily. Totally 8 doses

Documents available

D2710C00002_CSP.pdf
Download
CSR-D2710C00002.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

Quintiles London

+ 44 0800 634 1132

Investigators

Principal Investigator

Jan Eriksson

AstraZeneca